swog-8819 collecting, analyzing, and storing tissue samples from patients with non-hodgkin's lymphoma

Conditions: Lymphoma

Summary: rationale: collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in dna and identify biomarkers related to cancer. it may also help doctors learn how patients respond to treatment. purpose: this laboratory study is collecting, analyzing, and storing tissue samples from patients with non-hodgkin's lymphoma.

objectives: * establish a central lymphoma tissue repository of fresh snap-frozen tissue from patients with previously untreated non-hodgkin's lymphoma (nhl). * determine a standard set of procedures for routine acquisition, banking, and study of these tissue samples. * correlate presently activated phenotyping studies and future projected molecular studies of the dna and rna status of these tissue samples with clinical results. * correlate pretreatment phenotype or genotype of tissue samples from patients with intermediate- or high-grade nhl with patient outcome, in terms of complete response rate, time to progression, and survival. * correlate the lymphoma lineage (t-cell vs b-cell), loss of class ii human histocompatibility antigen status (hla-dr-positive vs hla-dr-negative), proliferative index (as measured by ki-67), and b- or t-cell antigen aberrancy (e.g., lack of pan b or t antigen expression) with outcome in patients with intermediate- or high-grade nhl. outline: patients are treated on the swog study on which they are enrolled. tissue samples obtained before treatment began are banked in a tissue repository. samples from patients with intermediate- or high-grade non-hodgkin's lymphoma are analyzed by three-stage immunohistochemistry using monoclonal antibodies to b-cell antigens, t-cell antigens, immunoglobulins, calla, hla-dr, anti-interleukin-2 receptor, and ki-67 (for the proliferative index). phenotype (immune marker status, proliferation status, and activation status) is correlated with response to treatment, relapse, and overall survival. projected accrual: approximately 495 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * registered on an active southwest oncology group (swog)-coordinated treatment protocol for previously untreated non-hodgkin's lymphoma * adequate pretreatment diagnostic tissue available meeting the following requirements: * fresh snap-frozen pretreatment diagnostic biopsy from any site (initial biopsy or rebiopsy) * 1 hematoxylin and eosin stained slide * 1 paraffin block and surgery pathology report patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: stage i adult diffuse large cell lymphoma stage i adult diffuse mixed cell lymphoma stage i adult diffuse small cleaved cell lymphoma stage ii adult diffuse large cell lymphoma stage ii adult diffuse mixed cell lymphoma stage ii adult diffuse small cleaved cell lymphoma stage iii adult diffuse large cell lymphoma stage iii adult diffuse mixed cell lymphoma stage iii adult diffuse small cleaved cell lymphoma stage iv adult diffuse large cell lymphoma stage iv adult diffuse mixed cell lymphoma stage iv adult diffuse small cleaved cell lymphoma stage i grade 3 follicular lymphoma stage ii grade 3 follicular lymphoma stage iii grade 3 follicular lymphoma stage iv grade 3 follicular lymphoma stage i adult immunoblastic large cell lymphoma stage ii adult immunoblastic large cell lymphoma stage iii adult immunoblastic large cell lymphoma stage iv adult immunoblastic large cell lymphoma stage i adult lymphoblastic lymphoma stage ii adult lymphoblastic lymphoma stage iii adult lymphoblastic lymphoma stage iv adult lymphoblastic lymphoma stage i adult burkitt lymphoma stage ii adult burkitt lymphoma stage iii adult burkitt lymphoma stage iv adult burkitt lymphoma